Clinical trials
Aggression clinical trials
Below are recruiting aggression clinical trials, each written for real people, not researchers. We’re tracking 88 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07168980RecruitingPhase 2/Phase 3
Chemotherapy plus rituximab for aggressive B-cell lymphoma in kids
This trial tests whether adding rituximab to standard chemotherapy works better for children and teens with aggressive B-cell non-Hodgkin lymphoma. It may be a good option if your child's cancer cells have the CD20 protein and they haven't been treated with rituximab before.
Shanghai, Shanghai MunicipalityAges Up to 18 years - NCT07162480RecruitingPhase 2
Investigational Drug for Advanced Salivary Gland Cancer (Adenoid Cystic Carcinoma)
This clinical trial studies an experimental drug called AZD8205 for people with a specific type of advanced adenoid cystic carcinoma (ACC). ACC is a rare cancer that usually starts in the salivary glands. The trial aims to see if the drug can shrink tumors or slow the disease, and it's for those whose cancer has spread or come back and fits certain molecular features.
Houston, TexasAges 18 years+ - NCT07156565RecruitingPhase 1
Study of actinium therapy for advanced soft tissue sarcoma
This trial is testing a new type of radiation therapy for advanced soft tissue sarcoma that has not responded to other treatments. The goal is to see if this therapy can shrink tumors and help control the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT07097363RecruitingPhase 2
Epcoritamab plus chemo for aggressive B-cell lymphoma
This trial tests a new drug, epcoritamab, added to a standard chemotherapy regimen (DA-EPOCH-R) for people with aggressive B-cell non-Hodgkin lymphoma that hasn't been treated before or has had only one round of chemo. It aims to see if this combination works better against certain high-risk types of lymphoma.
Seattle, WashingtonAges 18 years+ - NCT06244368RecruitingPhase 2
Chemo combo for relapsed aggressive lymphoma
This trial tests a combination of chemotherapy drugs (GVM, with or without rituximab) for people whose aggressive non-Hodgkin lymphoma has returned or not responded to standard treatment. It aims to find a new option that might work when others have stopped working.
Tianjin, Tianjin MunicipalityAges 18–65 - NCT07059741Recruiting
Radiation, stem cell transplant, and CAR-T for aggressive B-cell lymphoma
This trial tests a new approach that combines radiation therapy, a stem cell transplant, and a special immune cell treatment (CAR-T) for people with an aggressive type of B-cell lymphoma that has returned or stopped responding to standard treatments. The goal is to see if this powerful combination can help control the cancer better.
Suzhou, JiangsuAges 18 years+ - NCT07052578Recruiting
Aggressive prostate cancer study with HRR blood test
This study looks at men with aggressive, high-volume metastatic prostate cancer that is still sensitive to hormone therapy. It will analyze a blood test for HRR gene mutations (like BRCA) to help understand treatment patterns.
ArkhangelskAges 18 years+ - NCT07041606Recruiting
A study on advanced endometrial cancer in Russia
This study looks at genetic profiles and first treatments for advanced or aggressive endometrial cancer in women in Russia. It aims to understand how genetic information might guide better treatment choices.
ArkhangelskAges 18 years+ - NCT07002476RecruitingPhase 3
Early aggressive cholesterol-lowering after stroke with clot removal
This trial tests whether quickly starting an aggressive cholesterol-lowering treatment after a stroke improves recovery. It is for people who are about to have a procedure to remove a large blood clot from their brain.
ShanghaiAges 18 years+ - NCT06902649Recruiting
Step-by-step: A new care model for kids with anger or behavior issues
This study tests a step-by-step care model for children aged 8 to 16 who struggle with anger, defiance, or aggressive behavior. The goal is to see if offering different levels of support can help families manage these behaviors effectively.
SolnaAges 8–16 - NCT06875986Recruiting
Study of REXULTI for agitation in Alzheimer's disease
This trial is studying how a medication called REXULTI works in patients with Alzheimer's disease who have symptoms like excessive activity, aggression, or mood swings. It aims to see if the drug helps manage these behaviors.
Osaka, OsakaAges 15 years+ - NCT06665074RecruitingPhase 2
Inflammation and aggression study
This trial tests how inflammation affects aggression by giving a small amount of a substance that briefly triggers your immune system. You may qualify if you have a diagnosis of Intermittent Explosive Disorder (IED), or if you are a healthy control without current anger issues.
Columbus, OhioAges 21–55 - NCT06649812RecruitingPhase 2
Testing a combination targeted therapy (ViPOR) for aggressive B-cell lymphoma
This trial tests a new combination of targeted drugs called ViPOR for people with aggressive B-cell lymphoma that has come back or not responded to previous treatment. The goal is to see if this treatment can help when standard therapies haven't worked.
Tucson, ArizonaAges 18 years+ - NCT06579950Recruiting
Cool roofs and health study
This study tests whether a special cool roof coating can lower indoor temperatures and improve health. You may be eligible if you live in a home with a stable, safe roof.
OuagadougouAges 18 years+ - NCT06534437RecruitingPhase 2
Study of MEN1703 for aggressive B-cell lymphoma
This trial tests a new drug called MEN1703, alone or with another drug (glofitamab), for people with aggressive B-cell non-Hodgkin lymphoma that has come back or not responded after at least two prior treatments. The goal is to see if it can help shrink tumors.
Le MansAges 18 years+ - NCT06544265RecruitingPhase 1
SynKIR-310 for advanced B-cell lymphoma
This trial tests a new treatment called SynKIR-310 for people with B-cell non-Hodgkin lymphoma whose cancer has come back or not responded to at least 2 prior treatments. It may be an option if you've already had CAR T-cell therapy or cannot have it.
Denver, ColoradoAges 18 years+ - NCT06536049RecruitingPhase 1/Phase 2
Epcoritamab plus ibrutinib for relapsed or refractory aggressive B-cell lymphoma
This trial tests a combination of two drugs – epcoritamab (a type of immunotherapy that helps your immune system attack lymphoma cells) and ibrutinib (a targeted pill that blocks signals that help cancer grow). It is for people with aggressive B-cell lymphoma that has come back or not responded to at least 2 prior treatments.
Minneapolis, MinnesotaAges 18 years+ - NCT02833285Recruiting
Study immune cells in people with gum disease
This study looks at how the immune system (B cells) works in gum disease and may help doctors better understand the condition. You may be asked to take part if you need gum surgery and meet other health and treatment rules.
BrestAges 18–75 - NCT06271057RecruitingPhase 2
Golcadomide after CAR T-cell for high-risk large B-cell lymphoma
This trial tests a new drug, golcadomide, given after CAR T-cell therapy to prevent relapse in people with aggressive large B-cell lymphoma who are at high risk. If you've had or are about to receive CAR T-cells, this study may help keep your lymphoma in remission.
CréteilAges 18 years+ - NCT05783804Recruiting
Early cholesterol-lowering to help reverse artery plaque
This trial studies whether starting strong cholesterol-lowering treatment early can reduce or reverse plaque in the arteries. It may help protect the heart over time, especially for people with inherited high cholesterol.
Amsterdam, North HollandAges 18–50 - NCT06173518RecruitingPhase 1
CAR T-cell therapy for children with B-cell leukemia or lymphoma
This trial tests a CAR T-cell therapy that targets CD19 on cancer cells. It is for children whose B-cell acute lymphoblastic leukemia or aggressive B-cell non-Hodgkin lymphoma has come back or not responded to other treatments.
Los Angeles, CaliforniaAges birth–18 years - NCT06158880Recruiting
Alcohol and men's sexual risk behaviors
This study looks at how alcohol affects men's decisions about sex, especially risky behaviors like not using condoms. If you join, you may help researchers understand how to reduce HIV and STI risk.
Phoenix, ArizonaAges 21–30 - NCT06085729RecruitingPhase 1/Phase 2
Study of ADI-PEG20 with chemo for aggressive prostate cancer
This study tests a combination of three drugs—ADI-PEG20, carboplatin, and cabazitaxel—in men with aggressive variant prostate cancer that has stopped responding to hormone therapy. The goal is to see if this combination can shrink or slow the cancer.
Houston, TexasAges 18 years+ - NCT05996185RecruitingPhase 2
Study of mogamulizumab plus chemotherapy for T-cell lymphoma
This trial is testing a drug called mogamulizumab combined with standard chemotherapy (DA-EPOCH or CHOEP) for people with aggressive T-cell lymphoma. It aims to see if the combination is safe and works better than chemotherapy alone.
New Haven, ConnecticutAges 18 years+
Hear when a new Aggression trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for aggression?
- Yes. Clin2 currently lists 88 recruiting aggression studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a aggression trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a aggression trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.